CRISPR Therapeutics AG (CRSP) a Moderate Buy, Per Wall Street [Yahoo! Finance]
CRISPR Therapeutics AG - Common Shares (CRSP)
Last crispr therapeutics ag - common shares earnings: 8/7 05:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
nasdaq.com/symbol/crsp/real-time
Company Research
Source: Yahoo! Finance
CRISPR Therapeutics AG (NASDAQ:CRSP) is among the ARK Invest Stock Portfolio: Top 10 Stock Picks for 2026 with a stake value of over $551 million as of Q4 2025. The gene-editing company remains on analysts' radar and currently carries a Moderate Buy rating, with an average share price upside of 17% as of March 4. Recent updates include Truist Financial analyst Joon Lee reiterating the firm's Buy rating on the stock on March 2, according to TipRanks. Earlier on February 17, Chardan Capital lifted its price target on CRISPR Therapeutics AG (NASDAQ:CRSP) to $76 from $74 and maintained a Buy rating. The adjustment followed the company's business update and the announcement of its fourth-quarter results on February 12. CRISPR Therapeutics AG (CRSP) a Moderate Buy, Per Wall Street Jirsak/Shutterstock.com According to TipRanks, Chardan analyst Geulah Livshits highlighted the momentum in the company's siRNA therapies and vivo cardiovascular editing, along with progress across mul
Show less
Read more
Impact Snapshot
Event Time:
CRSP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRSP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRSP alerts
High impacting CRISPR Therapeutics AG - Common Shares news events
Weekly update
A roundup of the hottest topics
CRSP
News
- Is Crispr Therapeutics (CRSP) The Best Gene-Editing Stock to Buy Now? [Yahoo! Finance]Yahoo! Finance
- CRISPR Therapeutics (CRSP) had its "overweight" rating reaffirmed by Piper Sandler. They now have a $110.00 price target on the stock, up from $105.00.MarketBeat
- A Look At CRISPR Therapeutics (CRSP) Valuation After Upsized US$550 Million Convertible Note Offering [Yahoo! Finance]Yahoo! Finance
- Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know [Yahoo! Finance]Yahoo! Finance
- CRISPR Therapeutics (CRSP) Reports $116M FY25 Revenue Driven by CASGEVY Growth [Yahoo! Finance]Yahoo! Finance
CRSP
Earnings
- 2/12/26 - Miss
CRSP
Sec Filings
- 3/17/26 - Form 4
- 3/17/26 - Form 4
- 3/17/26 - Form 4
- CRSP's page on the SEC website